A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a multicenter, randomized, parallel study to evaluate the efficacy and safety of two doses of ENN0403 in subjects with diabetic macular edema (DME). Approximately 60 subjects will be randomized to receive ENN0403 capsule orally once a day at the low dose or high dose with a 1:1 ratio. The study period consisted of up to 2 weeks of screening, 12 weeks of treatment and 2 weeks of follow-up, and the entire trial period was up to 16 weeks.
Epistemonikos ID: 1a0ef44159d848fa5c8a38776ce9631b7c0bdc05
First added on: Dec 01, 2024